INCYTE CORPORATION Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
INCYTE CORPORATION (INCY) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $5.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-10
- INCYTE CORPORATION unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2024-12-31 was $3.80M, a 72.73% increase year-over-year.
- INCYTE CORPORATION unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2024-09-30 was $1.70M.
- INCYTE CORPORATION unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2024-06-30 was $1.60M.
- INCYTE CORPORATION unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2024-03-31 was $1.40M.
- INCYTE CORPORATION unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $5.60M, a 34.12% decline from fiscal 2024.
- INCYTE CORPORATION unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $8.50M, a 73.47% increase from fiscal 2023.
- INCYTE CORPORATION unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $4.90M, a 28.95% increase from fiscal 2022.
- INCYTE CORPORATION unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $3.80M, a 533.33% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 3 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 6 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 9 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.60M 10-K · filed 2026-02-10 | |||
| 2024-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $5.50M derived: sum of 2 quarters · filed 2026-02-10 | $7.10M derived: sum of 3 quarters · filed 2026-02-10 | $8.50M 10-K · filed 2026-02-10 |
| 2024-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $3.30M derived: sum of 2 quarters · filed 2024-10-29 | $4.70M 10-Q · filed 2024-10-29 | $6.90M derived: sum of 4 quarters · filed 2025-02-10 |
| 2024-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $3.00M 10-Q · filed 2024-07-30 | $5.20M derived: sum of 3 quarters · filed 2025-02-10 | $5.10M derived: sum of 4 quarters · filed 2025-02-10 |
| 2024-03-31 | $1.40M 10-Q · filed 2024-04-30 | $3.60M derived: sum of 2 quarters · filed 2025-02-10 | $3.50M derived: sum of 3 quarters · filed 2025-02-10 | |
| 2023-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $2.10M derived: sum of 2 quarters · filed 2025-02-10 | $4.90M 10-K · filed 2025-02-10 | |
| 2023-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $2.70M 10-Q · filed 2023-10-31 | ||
| 2023-06-30 | $2.80M 10-Q · filed 2023-08-01 | |||
| 2022-12-31 | $3.80M 10-K · filed 2024-02-13 | |||
| 2021-12-31 | $600.00K 10-K · filed 2023-02-07 | |||
| 2019-12-31 | $200.00K 10-K · filed 2021-02-09 | |||
| 2018-12-31 | $100.00K 10-K · filed 2021-02-09 | |||
| 2017-12-31 | $300.00K 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $300.00K 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |